Live Breaking News & Updates on Oncology Ljubljana|Page 7
Stay updated with breaking news from Oncology ljubljana. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Synovial sarcoma and myxoid round cell liposarcoma are rare, chemo-refractory malignancies with a poor prognosis once metastasized. Current treatment regimens are limited, and a ....
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly higher rates of grade 3 or higher adverse events compared to the placebo-chemoradiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Pembrolizumab has demonstrated efficacy in advanced cervical cancer, prompting an investigation into its potential ....
A healthcare provider may recommend nuclear medicine procedure to diagnose or treat a health problem. It shows how the organs or tissues are functioning. TheHealthSite.com ....
Breast cancer patients more likely to develop second cancer in lifetime: Study beckershospitalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from beckershospitalreview.com Daily Mail and Mail on Sunday newspapers.
1. For patients with localized endometrial cancer recurrence, adding cisplatin to radiation therapy did not appear to improve progression-free survival when compared to radiation therapy alone. 2. For patients with localized endometrial cancer recurrence, adding cisplatin to radiation therapy resulted in higher rates of acute toxicity, when compared to radiation therapy alone. Evidence Rating Level: ....